VIENNA, Va., Oct. 30 /PRNewswire-FirstCall/ -- CEL-SCI Corporation
(Amex: CVM) announced that Geert Kersten, Chief Executive Officer, will be
presenting at the Rodman & Renshaw 9th Annual Healthcare Conference being
held at the New York Plaza Hotel from November 5-7, 2007. The presentation
will be focused on its Phase III cancer product Multikine(R) which is the
first biotech cancer product seeking to become a new first line standard of
care treatment in cancer.
Mr. Kersten's presentation will be on Wednesday, November 7th, at 1:40
p.m. EDT. The presentation will be webcast live with slides and archived
for 90 days after the conference. The webcast can be accessed at
http://www.wsw.com/webcast/rrshq12/cvm or http://www.cel-sci.com.
About CEL-SCI's Phase III Cancer Drug Multikine:
In Phase II clinical trials Multikine was shown to be safe and well-
tolerated, and to improve the patients' overall survival by 33% at a median
of three and a half years following surgery. The U.S. Food and Drug
Administration (FDA) gave the go-ahead for a Phase III clinical trial with
Multikine in January 2007 and granted orphan drug status to Multikine in
the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and
neck in May 2007.
Multikine, a patented defined mixture of naturally derived cytokines,
is the first immunotherapeutic agent in a new class of drugs called "Immune
SIMULATORS." Immune SIMULATORS simulate the way our natural immune system
acts in defending us against cancer. As opposed to other immunotherapies
which are designed to target a single or limited number of specific
antigens or molecules, Immune SIMULATORS are multi-targeted; they
simultaneously cause a direct and targeted killing of the specific tumor
cells and they activate the immune system to produce a stronger anti-tumor
attack on multiple fronts.
Multikine is also the first immunotherapeutic agent being developed as
a first-line standard of care treatment for cancer. It is administered
prior to any other cancer therapy because that is the period when the
anti-tumor immune response can still be fully activated. Once the patient
has advanced disease, or had surgery or has received radiation and/or
chemotherapy, the immune system is severely weakened and is less able to
mount an effective anti-tumor immune response. Other immunotherapies are
administered after the patient has received chemotherapy and/or radiation
therapy, which can limit their effectiveness.
The Company has operations in Vienna, Virginia and Baltimore, Maryland.
CEL-SCI's other products, which are currently in pre-clinical stage, have
shown protection against a number of diseases in animal tests and are being
tested against diseases associated with bio-defense and avian flu.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com
http://www.wsw.com/webcast/rrshq12/cvm
CONTACT:
Gavin de Windt of CEL-SCI Corporation,
+1-703-506-9460
|
